Literature DB >> 8745314

Identification of hepatitis C virus by immunoelectron microscopy.

X Li1, L J Jeffers, L Shao, K R Reddy, M de Medina, J Scheffel, B Moore, E R Schiff.   

Abstract

Sequencing of the hepatitis C virus (HCV) has provided a better understanding of the natural history, immunology, and epidemiology of this virus. However, the morphology of HCV has not been definitively characterized. In this study, through a sequence of concentration processes, virus-like particles were isolated from human serum and liver tissue, visualized by transmission electron microscopy and identified as hepatitis C virion by immunoelectron microscopy. Spherical flavi-like virus particles, approximately 70 nm in diameter, were observed in the fraction with 1.04-1.12 g ml-1 sucrose density and bound to immunogold particles with monoclonal antibodies (mAb) against hepatitis C. The nucleocapsid of the particles, which were 50 nm in diameter, appeared to be icosahedral in structure and surrounded by an envelope covered with surface projections. A 'tadpole' form of particles was also observed. The findings indicate that the low buoyant density in sucrose and the morphological features of the hepatitis C virion are consistent with the characteristics of flaviviruses and pestiviruses.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8745314     DOI: 10.1111/j.1365-2893.1995.tb00034.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  9 in total

1.  Construction of the Vero cell culture system that can produce infectious HCV particles.

Authors:  Jia Guo; Ran Yan; Guodong Xu; Weiyun Li; Congyi Zheng
Journal:  Mol Biol Rep       Date:  2007-10-25       Impact factor: 2.316

Review 2.  Histopathology and detection of hepatitis C virus in liver.

Authors:  P J Scheuer; K Krawczynski; A P Dhillon
Journal:  Springer Semin Immunopathol       Date:  1997

3.  Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector.

Authors:  Heather J Ezelle; Dubravka Markovic; Glen N Barber
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

4.  Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture.

Authors:  Pablo Gastaminza; Kelly A Dryden; Bryan Boyd; Malcolm R Wood; Mansun Law; Mark Yeager; Francis V Chisari
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

Review 5.  Hepatitis C virus relies on lipoproteins for its life cycle.

Authors:  Germana Grassi; Giorgia Di Caprio; Gian Maria Fimia; Giuseppe Ippolito; Marco Tripodi; Tonino Alonzi
Journal:  World J Gastroenterol       Date:  2016-02-14       Impact factor: 5.742

6.  Baculovirus mediated production of infectious hepatitis C virus in human hepatoma cells stably expressing T7 RNA polymerase.

Authors:  Xiangjie Yao; Qingxia Han; Jianhua Song; Changyong Liang; Takaji Wakita; Rongge Yang; Xinwen Chen
Journal:  Mol Biotechnol       Date:  2008-06-10       Impact factor: 2.695

7.  Antiviral stilbene 1,2-diamines prevent initiation of hepatitis C virus RNA replication at the outset of infection.

Authors:  Pablo Gastaminza; Suresh M Pitram; Marlene Dreux; Larissa B Krasnova; Christina Whitten-Bauer; Jiajia Dong; Josan Chung; Valery V Fokin; K Barry Sharpless; Francis V Chisari
Journal:  J Virol       Date:  2011-03-23       Impact factor: 5.103

8.  Nonstructural protein 5A is incorporated into hepatitis C virus low-density particle through interaction with core protein and microtubules during intracellular transport.

Authors:  Chao-Kuen Lai; Vikas Saxena; Chung-Hsin Tseng; King-Song Jeng; Michinori Kohara; Michael M C Lai
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

9.  Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients.

Authors:  Søren U Nielsen; Margaret F Bassendine; Alastair D Burt; Caroline Martin; Wanna Pumeechockchai; Geoffrey L Toms
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.